BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Ifezuntirgene inilparvovec readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Ifezuntirgene inilparvovec\, from Clinica
 lTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05243017-10915@assetmemo.bio
DTSTAMP:20261121T010016Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Ifezuntirgene inilparvovec: Phase 1/2 readout est. (NCT05243017)
DESCRIPTION:Ifezuntirgene inilparvovec\, phase 1/2\, Huntington's Disease.\
 nStudy: Safety and Efficacy of AMT-130 in European Adults With Early Manif
 est Huntington's Disease\nEstimated primary completion: March 2029. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/ifezuntirgene-inilparvovec#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0524
 3017
URL:https://assetmemo.bio/drug/ifezuntirgene-inilparvovec#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04120493-10915@assetmemo.bio
DTSTAMP:20261121T010016Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Ifezuntirgene inilparvovec: Phase 1/2 readout est. (NCT04120493)
DESCRIPTION:Ifezuntirgene inilparvovec\, phase 1/2\, Huntington's Disease.\
 nStudy: Safety and Proof-of-Concept (POC) Study With AMT-130 in Adults Wit
 h Early Manifest Huntington's Disease\nEstimated primary completion: June 
 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/ifezuntirgene-i
 nilparvovec#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT04120493
URL:https://assetmemo.bio/drug/ifezuntirgene-inilparvovec#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
